This site is intended for healthcare professionals in United Arab Emirates




Sign InLog Out Our MedicinesTherapy AreasExplore ContentExplore ContentDownloadable materials
Let's ConnectLet's ConnectContact usPfizer medical information

Adverse event reporting can be found at the bottom of the page



MOA MOA MOA EfficacyEfficacyPALOMA-2 Study designPatient Characteristics Primary endpoint Secondary end point PALOMA-3Study design Patient Characteristics Primary endpoint Secondary end point SurvivalFinal analysis Subgroup analysis Prespecified groups Updated Subgroup analysis Safety Safety PALOMA pooled analysis Adverse reactions  & Laboratory abnormalities PALOMA 2 Adverse Events PALOMA 3 Adverse Events IBRANCE consistent  safety profile Pooled analysis of patients aged ≥65 years in the PALOMA trials No evidence of cumulative or delayed toxicity with up to 50 months Patients with visceral diseases GI ,  Liver toxicities, and QTC Dosing Dosing Once daily dosing Dose Modification Real-World EvidenceReal-world EvidenceIBRANCE is the only CDK4/6 inhibitor with >5 years of real-world experience Real-world data provide additional information Favorable progression free rates IRIS Study In the real world, IBRANCE benefits GuidelinesGuidelinesNCCN Guidelines ESMO Guidelines Support & Services Support & Resources Patient support program/tools Events Materials Videos
Ibrance®  US Prescribing Information  Click Here
The PALOMA-3 OS final analysis of IBRANCE + fulvestrant in first-line or later treatment demonstrated a numerical difference in favour of IBRANCE + fulvestrant versus placebo + fulvestrant that did not reach statistical significance1,2Adapted from Ibrance SmPC.2
Data cut-off date: 13 April 2018.
*Not statistically significant at the prespecified significance level of 0.0235 (one-sided).2
1-sided P value from the log-rank test stratified by the presence of visceral metastases and sensitivity to prior ET per randomisation.2
CI = confidence interval; ET= endocrine treatment; FUL = fulvestrant; HR = hazard ratio; OS = overall survival; PALOMA-3 = the palbociclib ongoing trials in the management of breast cancer 3; PLA = placebo; RCT = randomised controlled trial;  SmPC = summary of product characteristics.

References: 1. Turner NC, et al. N Engl J Med. 2018;379(20):1926-1936. 2. Master Gulf Levant-LPD-(Ibrance)-Capsules - 75 mg, 100 mg & 125 mg based on USPI date of Revision: December 2022 for UAE.
Difference in median OS (not statistically significant) was observed across most subgroups, with estimated OS HRs similar to the OS HR of the overall ITT population1
  • Randomisation in PALOMA-3 was stratified according to the presence/absence of visceral metastasis, menopausal status at study entry and sensitivity to prior ET1
  • This analysis is not intended to demonstrate efficacy in a particular subgroup and is further limited by small numbers of patients in some subpopulations
Adapted from Turner NC, et al. 2018.1
Data cut-off date: 13 April 2018.
CI = confidence interval; ER = oestrogen receptor; ET = endocrine therapy; FUL = fulvestrant; HR = hazard ratio; ITT = intention-to-treat; NE = not estimable; OS = overall survival; PALOMA-3 = the palbociclib ongoing trials in the management of breast cancer 3; PLA = placebo; PR = progesterone receptor.

Reference: 1. Turner NC, et al. N Engl J Med. 2018;379(20):1926-1936.

Prescribing Information: Master GULF LEVANT-LPD- (Ibrance)- Capsules- 75 mg, 100 mg &125 mg based on USPI Revision date: December 2022 – United Arab Emirates


Report Adverse Events 

If you'd like to report an adverse event related to a Pfizer Product from Gulf (UAE, Bahrain, Qatar, Oman and Kuwait), please send an email with the adverse event details to: [email protected]

Pfizerpro accountPfizerPro Account

Access Pfizer materials, resources and receive communications from Pfizer about our products with a Pfizerpro account.

Sign inRegisterAccountSign Out

Copyright © 2023 Pfizer Gulf FZ LLC. All rights reserved.


i- The product information provided in this site is intended only for Healthcare Professionals of UAE. The products discussed herein may have different product labeling in different countries.


ii- The information provided on this website is intended only for healthcare professionals of UAE.